Market open
Summit Therapeutics/$SMMT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Summit Therapeutics
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Ticker
$SMMT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
159
ISIN
US86627T1088
Website
SMMT Metrics
BasicAdvanced
$17B
-
-$0.34
-0.46
-
Price and volume
Market cap
$17B
Beta
-0.46
52-week high
$36.91
52-week low
$2.10
Average daily volume
5.6M
Financial strength
Current ratio
10.63
Quick ratio
10.36
Long term debt to equity
0.844
Total debt to equity
1.873
Interest coverage (TTM)
-42.31%
Management effectiveness
Return on assets (TTM)
-52.50%
Return on equity (TTM)
-123.93%
Valuation
Price to book
49.73
Price to tangible book (TTM)
50.01
Price to free cash flow (TTM)
-89.032
Growth
Earnings per share change (TTM)
105.02%
3-year earnings per share growth (CAGR)
-29.38%
What the Analysts think about SMMT
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Summit Therapeutics stock.
SMMT Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
SMMT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
SMMT News
AllArticlesVideos
Why Is Summit Therapeutics Stock Trading Higher On Monday?
Benzinga·3 weeks ago
What's Going On With Summit Therapeutics Stock On Friday?
Benzinga·3 weeks ago
Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Summit Therapeutics stock?
Summit Therapeutics (SMMT) has a market cap of $17B as of May 16, 2025.
What is the P/E ratio for Summit Therapeutics stock?
The price to earnings (P/E) ratio for Summit Therapeutics (SMMT) stock is 0 as of May 16, 2025.
Does Summit Therapeutics stock pay dividends?
No, Summit Therapeutics (SMMT) stock does not pay dividends to its shareholders as of May 16, 2025.
When is the next Summit Therapeutics dividend payment date?
Summit Therapeutics (SMMT) stock does not pay dividends to its shareholders.
What is the beta indicator for Summit Therapeutics?
Summit Therapeutics (SMMT) has a beta rating of -0.46. This means that it has an inverse relation to market volatility.